Johnson & Johnson has reported Q1 2026 revenue of $24.06 billion, aligning with expectations and reflecting a revenue surprise of 1.89%. The healthcare giant's normalized earnings per share came in at $2.70, also meeting estimates, which contributed to a recent upgrade to 'Outperform' by analysts. Additionally, J&J has increased its quarterly dividend to $1.34, marking 64 consecutive years of growth in shareholder returns, further solidifying its position as a resilient performer in the market.
“J&J · launched oral pill · Icotyde for plaque psoriasis · true”
“Johnson & Johnson · Q1 2026 Normalized EPS · estimate · 2.70”
“Johnson & Johnson · Q1 2026 Revenue · estimate · 24.06B”
“Johnson & Johnson · Revenue · Q1 2026 · 24.06B”
“Johnson & Johnson · Q1 2026 EPS surprise · percentage · +0.85%”
“Johnson & Johnson · Q1 2026 Revenue surprise · percentage · +1.89%”
“Johnson & Johnson · Q1 2026 Normalized EPS · actual · 2.70”
“Johnson & Johnson · was upgraded to · Outperform · from Market Perform”
“Johnson & Johnson · was upgraded to · Outperform · from Market Perform”
“Johnson & Johnson · just raised its quarterly dividend to · $1.34 · extending its streak to 64 consecutive years”
“Johnson & Johnson · generates roughly · two dollars of operating cash · for every dollar sent to shareholders”
“Johnson & Johnson (JNJ) · Market Cap · Market Cap · $554.623B”
